SIADH

The syndrome of inappropriate antidiuretic hormone (SIADH) secretion is characterized by pathological production of antidiuretic hormone (ADH, also called vasopressin) leading to euvolemic hyponatremia with inappropriately concentrated urine. SIADH represents one of the most common causes of hyponatremia in hospitalized patients, with prevalence ranging from 4-11% depending on the underlying etiology and patient population studied. The condition is clinically significant because acute or severe hyponatremia can precipitate life-threatening neurological complications including cerebral edema, seizures, and death, making prompt recognition and treatment essential. Understanding SIADH is high-yield for board examinations due to its frequency, the importance of distinguishing it from other causes of hyponatremia, and the nuances of fluid restriction as first-line therapy. The syndrome occurs when ADH secretion becomes independent of normal osmotic and hemodynamic regulation, resulting in water retention that suppresses serum sodium concentration despite normal or high total body water.

Under normal conditions, ADH secretion is regulated by two primary mechanisms: osmotic regulation (primary driver) and hemodynamic regulation (secondary). Osmoreceptors in the hypothalamus (specifically in the supraoptic and paraventricular nuclei) detect changes in serum osmolality with exquisite sensitivity; osmolality increases of just 1-2% suppress ADH secretion, while increases of 8-10% cause maximal ADH release. ADH acts on V2 receptors in the collecting duct of the nephron, activating adenylyl cyclase and increasing aquaporin-2 (AQP2) water channel expression on the apical membrane, thereby increasing water reabsorption and concentrating the urine. In SIADH, the fundamental pathophysiologic defect is autonomous or inappropriately stimulated ADH secretion that becomes dissociated from normal feedback control, meaning ADH levels remain elevated despite low or normal serum osmolality, and continued water reabsorption occurs despite osmolality suppression.

The mechanism driving hyponatremia in SIADH involves positive free water balance. Because ADH remains elevated despite normal or suppressed osmolality, the collecting duct continues to reabsorb water isoosmotically, creating a state where fluid intake (both oral fluids and those from metabolic pathways) exceeds fluid excretion. The kidneys cannot generate appropriately dilute urine; instead, urine osmolality remains >200 mOsm/kg despite serum osmolality falling below 270 mOsm/kg (the normal osmotic threshold for ADH suppression is approximately 280-290 mOsm/kg). This creates progressive dilution of plasma sodium as water enters cells osmotically; the serum sodium falls while total body sodium remains normal or near-normal, defining the euvolemic nature of SIADH. The rate of sodium decline is crucial clinically—rapid drops in sodium (>12 mEq/L in 24 hours) cause cerebral cell edema as water influx exceeds the brain's ability to eliminate intracellular osmolytes, resulting in acute neurological symptoms.

A critical feature of SIADH pathophysiology is that despite water retention and hypervolemia at the cellular level, patients typically appear clinically euvolemic without peripheral edema, ascites, or elevated jugular venous pressure. This occurs because the excess water distributes intracellularly (due to osmotic equilibration) rather than accumulating in the extracellular space as interstitial edema. The mild expansion of extracellular fluid volume (ECF) that does occur triggers compensatory increases in atrial natriuretic peptide (ANP) and renal perfusion pressure, leading to natriuresis that helps minimize peripheral edema formation. However, this natriuresis paradoxically worsens hyponatremia because urinary sodium excretion increases while ADH-mediated water reabsorption persists, creating a syndrome where sodium depletion occurs concurrently with water retention—a phenomenon sometimes termed "salt wasting" in the context of SIADH.

The brain responds to chronic hyponatremia through osmolyte adaptation, a protective mechanism that both benefits and complicates SIADH management. Intracellular osmolytes—including amino acids (glutamate, taurine), polyols (sorbitol, inositol), and methylamines—decrease in the setting of chronic hyponatremia, reducing the osmotic gradient driving water influx and thereby minimizing cerebral edema. Organic osmolytes are extruded via specific transporters (taurine transporter, myo-inositol transporter) in response to cell swelling over hours to days. This adaptation is protective in chronic SIADH (preventing seizures despite sodium levels of 110-120 mEq/L) but creates a major clinical consequence: rapid correction of hyponatremia can precipitate osmotic demyelination syndrome (ODS) because the suddenly hypertonic extracellular fluid drives water out of cells faster than osmolytes can be regenerated, causing cellular dehydration and demyelination in the pons and extrapontine regions.

Malignancies account for approximately 40-50% of SIADH cases and represent the single most common identifiable cause in many cohorts. Small cell lung cancer (SCLC) is the classic malignancy associated with SIADH, occurring in 10-15% of SCLC patients; cancer cells produce ectopic ADH directly or stimulate ADH release through paracrine mechanisms. Other malignancies frequently associated with SIADH include non-small cell lung cancer (particularly adenocarcinoma), gastric cancer, pancreatic cancer, bladder cancer, lymphomas (especially small cell lymphomas and hodgkin lymphoma), and mesothelioma. The ectopic ADH is typically produced by neuroendocrine elements within the tumor, and SIADH may be the presenting manifestation of occult malignancy in some patients.

Intrathoracic pathology causes SIADH through several mechanisms including direct stimulation of hypothalamic ADH-producing neurons via vagal afferents, ADH production by inflammatory cells, and increased sympathetic tone triggering ADH release. Pneumonia (particularly bacterial and atypical organisms like mycoplasma) is the most frequent pulmonary cause, occurring in 2-10% of pneumonia patients and often self-limited as infection resolves. Tuberculosis, particularly with miliary or endobronchial disease, causes SIADH through both direct pulmonary infection and associated meningitis. Positive pressure ventilation (including CPAP and mechanical ventilation) increases intrathoracic pressure and triggers ADH release through baroreceptor mechanisms. Other pulmonary etiologies include cystic fibrosis, asthma exacerbations, pneumothorax, pulmonary embolism, and chronic obstructive pulmonary disease.

Hypothalamic and pituitary pathology can directly impair normal ADH regulation by damaging osmoreceptors or causing ectopic ADH production. Traumatic brain injury and post-neurosurgery states (particularly transsphenoidal hypophysectomy or pituitary surgery) are common causes in hospitalized patients, presumably from direct hypothalamic damage or irritation. Meningitis and encephalitis (particularly bacterial, viral, and fungal meningitis) cause SIADH through inflammatory activation of hypothalamic nuclei. Subarachnoid hemorrhage frequently precipitates SIADH, often in association with hyponatremia-related deterioration in neurological status. Other CNS etiologies include multiple sclerosis, head and neck trauma (facial fractures, basilar skull fractures), stroke, tumor (pituitary adenoma, craniopharyngioma, meningioma), and intracranial mass effect from any cause.

Numerous medications induce SIADH by stimulating ADH release or enhancing renal responsiveness to ADH. Selective serotonin reuptake inhibitors (SSRIs) represent a major and frequently encountered drug class causing SIADH, with incidence of approximately 0.5-15% depending on the agent and patient risk factors; fluoxetine, sertraline, and paroxetine have the highest reported incidence. Carbamazepine is a classic medication cause of SIADH, occurring in 10-20% of treated patients. Vincristine and other vinca alkaloids cause SIADH through neurologic mechanisms. Other medications include desmopressin (exogenous ADH), oxytocin, chlorpropamide (enhances renal ADH sensitivity), NSAIDs (reduce renal perfusion and trigger ADH), thiazide diuretics (though paradoxically deplete body sodium and can cause hyponatremia through ADH-independent mechanisms), and 3,4-methylenedioxymethamphetamine (MDMA/ecstasy). Tricyclic antidepressants, barbiturates, phenothiazines, and haloperidol also cause SIADH.

Infections represent a major SIADH etiologic category, including not only primary pulmonary infections but also bacterial, viral, fungal, and parasitic systemic infections. Legionella pneumophila historically had a strong association with SIADH (up to 30% of cases in some early series). HIV/AIDS causes SIADH both directly through CNS opportunistic infections (toxoplasmosis, cryptococcal meningitis, CMV encephalitis) and through associated opportunistic infections like Pneumocystis pneumonia. Tuberculous meningitis is a particularly important cause in endemic regions. Viral meningitis, particularly enteroviral meningitis, causes SIADH. Aspergillus infections and other systemic fungal infections can trigger SIADH.

Idiopathic SIADH (formerly termed "essential hyponatremia") represents approximately 20-30% of SIADH cases where no identifiable underlying cause is discovered despite thorough evaluation; this category likely encompasses undiagnosed etiologies and primary hypothalamic dysfunction. Hypothyroidism and adrenal insufficiency can contribute to hyponatremia by both ADH-dependent and ADH-independent mechanisms. Aging is a significant risk factor, with increased SIADH incidence in elderly patients possibly related to baseline ADH elevation and altered osmotic suppression. Psychogenic polydipsia (excessive water drinking in psychiatric patients) creates hyponatremia through water overload rather than true SIADH, though distinguishing these can be challenging clinically.

The clinical manifestations of SIADH-associated hyponatremia vary dramatically based on the rate of sodium decline and the absolute serum sodium concentration. Acute hyponatremia (developing over <48 hours) produces more severe neurological symptoms at higher absolute sodium levels because osmolyte adaptation has not yet occurred, meaning greater osmotic gradient drives water into the brain. Early symptoms of acute hyponatremia include nausea (caused by activation of chemoreceptors in response to brain cell swelling), malaise, headache (from increased intracranial pressure due to cerebral edema), and personality changes or confusion. As severity progresses, patients develop restlessness, irritability, disorientation, and lethargy reflecting progressive cerebral edema. Seizures may occur with acute hyponatremia at sodium levels of 125-130 mEq/L or higher if the decline is rapid, though seizure threshold varies based on rate of change.

Chronic hyponatremia (developing over >48 hours) often remains asymptomatic even at quite low sodium levels (110-120 mEq/L) because osmolyte adaptation minimizes brain cell volume expansion. These patients may present with only subtle findings including mild nausea, anorexia, muscle cramps, or fatigue attributable to mild hyponatremia itself or to the underlying SIADH etiology. The lack of symptoms can be deceptively reassuring but dangerous because rapid correction attempts in apparently stable patients with chronic hyponatremia can precipitate osmotic demyelination syndrome. Some patients with chronic hyponatremia report difficulty concentrating, memory impairment, or gait disturbance that may be attributed to underlying neuropsychiatric illness rather than hyponatremia itself.

Severe acute hyponatremia (sodium <120 mEq/L developing rapidly) produces a medical emergency with generalized seizures, coma, respiratory depression, cerebral herniation, and potential death if sodium correction is delayed. These manifestations result from massive cerebral edema overwhelming the skull's ability to accommodate volume expansion. Pulmonary edema can occur with severe hyponatremia, representing another mechanism of respiratory compromise. The temporal relationship between symptom onset and measured sodium helps distinguish acute from chronic hyponatremia—patients presenting with seizures at sodium of 128 mEq/L likely have acute hyponatremia, while asymptomatic patients with sodium of 118 mEq/L likely have chronic hyponatremia with osmolyte adaptation.

Clinical presentation often reflects the underlying cause of SIADH rather than hyponatremia itself. Patients with malignancy-induced SIADH present with constitutional symptoms (weight loss, fatigue, cough) and may have hyponatremia as an incidental finding on routine lab work or as a presenting manifestation prompting cancer diagnosis. Patients with pulmonary SIADH (pneumonia, TB) present with respiratory symptoms (cough, dyspnea, fever) with hyponatremia as a concurrent finding. Patients with medication-induced SIADH may present with symptoms of the underlying condition being treated (depression in SSRI users) complicated by hyponatremia symptoms overlapping with psychiatric manifestations. Patients with CNS pathology present with neurological findings (focal deficits from stroke, decreased consciousness after head trauma) with concurrent hyponatremia.

The physical examination in SIADH characteristically demonstrates euvolemia with absence of typical volume depletion (normal blood pressure, normal jugular venous pressure, absence of tachycardia) and absence of typical volume overload findings (no peripheral edema, no ascites, no pulmonary crackles from pulmonary edema). This distinguishes SIADH from other hyponatremia etiologies clinically—hypovolemic hyponatremia presents with hypotension, elevated heart rate, decreased JVP, and dry mucous membranes, while hypervolemic hyponatremia presents with hypertension, elevated JVP, peripheral edema, and pulmonary crackles. Neurological examination findings vary based on hyponatremia severity and acuity; patients with acute symptomatic hyponatremia may demonstrate confusion, disorientation, seizure activity, hyperreflexia, Babinski signs (suggesting severe cerebral edema), or altered level of consciousness. Vital signs are typically normal in uncomplicated SIADH unless underlying pulmonary or CNS disease is present.

SIADH in the postoperative period typically develops 24-

SIADH is a diagnosis of exclusion established by the Bartter and Schwartz criteria, which remain the reference standard and are reproduced in essentially all current US and European hyponatremia guidance (2013 US expert panel recommendations; 2014 ESE/ESICM/ERA-EDTA clinical practice guideline).

Etiologic workup: chest imaging for small cell lung cancer, brain imaging for CNS disease, and a careful medication review (SSRIs, carbamazepine, vincristine).

Management is decided by symptom severity and rate of onset, not by the absolute sodium number.